Holen Sie sich die Stockscreener-App
176.30
0.54%
1.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$175.30
Offen:
$177.65
24-Stunden-Volumen:
2.30M
Relative Volume:
1.32
Marktkapitalisierung:
$25.86B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.87
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+7.02%
1M Leistung:
+17.58%
6M Leistung:
+40.08%
1J Leistung:
+11.61%
1-Tages-Spanne:
$175.57
$185.17
1-Wochen-Bereich:
$163.00
$185.17
52-Wochen-Spanne:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
176.27 | 25.72B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,064.45 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.44 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
230.28 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.56 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.01 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Dayra Therapeutics secures Biogen partnership and $70M before officially opening its doors - The Business Journals
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data? - Benzinga
Novo Nordisk’s Alzheimer’s Trials Were a Long Shot. Their Failure Is Still Hitting the Stock. - Barron's
Biogen and Dayra in deal over oral macrocyclic peptides - The Pharma Letter
Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact - Reuters
Biogen stock hits 52-week high at 177.37 USD By Investing.com - Investing.com Canada
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies By Investing.com - Investing.com Canada
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership - BioSpace
Biogen (BIIB) Partners with Dayra Therapeutics to Develop Oral M - GuruFocus
Biogen, Dayra Therapeutics Collaborate to Develop Oral Macrocyclic Peptides - MarketScreener
Novo Nordisk’s Alzheimer’s Trials Always Were a Long Shot. The Stock Is Falling Anyway. - Barron's
Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial - Benzinga
Biogen, Dayra Therapeutics Partner To Develop Oral Macrocyclic Peptides For Immunological Diseases - Nasdaq
Novo Nordisk shares plunge as oral semaglutide Alzheimer’s trial fails to show clinical benefit - TradingView
Biogen, Dayra Therapeutics to collaborate on developing oral macrocyclic peptides - MarketScreener
Biogen partners with Dayra to develop oral macrocyclic peptides - Investing.com
Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials - TradingView
Biogen, Dayra Therapeutics To Collaborate On Developing Oral Macrocyclic Peptides - TradingView
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions - Biogen
Biogen (Nasdaq: BIIB), Dayra to Develop Oral Macrocyclic Peptides for Immunology - Stock Titan
Biogen Reaches Research Deal With Dayra in Immunology Push - Bloomberg.com
Eli Lilly stock falls, Biogen rises after Novo’s Alzheimer’s trial failure - Investing.com Canada
Biogen (BIIB): Evaluating Valuation as Regulatory Wins and New Data Spark Investor Interest - simplywall.st
Piper Sandler Reiterates Biogen (BIIB) Neutral Recommendation - Nasdaq
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
Piper Sandler Reiterates Neutral Rating on Biogen (BIIB), Raises Price Target | BIIB Stock News - GuruFocus
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer'sNovo Nordisk (NYSE:NVO) - Benzinga
Piper Sandler Adjusts Price Target on Biogen to $157 From $118, Maintains Neutral Rating - MarketScreener
Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix… - MarketScreener
How analysts rate Biogen Inc. stock todayFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Biogen Reports New Lecanemab Findings on Subcutaneous Administration and Long-Term Benefits Ahead of CTAD Conference - Quiver Quantitative
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference - Biogen
Biogen (Nasdaq: BIIB) to share lecanemab subcutaneous initiation data at CTAD 2025 - Stock Titan
How reliable is Biogen Inc. (IDP) stock dividend growthWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - newser.com
Japan Neurology Clinical Trials Market to Get an Explosive Growth | Biogen, IQVIA, Thermo Fisher Scientific - openPR.com
Is Biogen Inc. (IDP) stock a buy before earnings resultsRecession Risk & Fast Exit/Entry Strategy Plans - newser.com
Chart based exit strategy for Biogen Inc.GDP Growth & Step-by-Step Trade Execution Guides - newser.com
Analyzing Biogen Inc. with multi timeframe charts2025 Trading Volume Trends & Growth-Oriented Investment Plans - newser.com
Will Biogen Inc. (IDP) stock benefit from commodity supercycleWeekly Stock Summary & Free Expert Verified Stock Movement Alerts - newser.com
Will Biogen Inc. stock reach all time highs in 20252025 Winners & Losers & Daily Profit Focused Screening - newser.com
Key metrics from Biogen Inc.’s quarterly dataWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Why Biogen Inc. stock is considered a top pick2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - newser.com
Why Biogen Inc. (IDP) stock benefits from AI revolutionPortfolio Gains Report & Daily Stock Trend Reports - newser.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen to Participate in Upcoming Investor Conferences - Biogen
A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results - Yahoo Finance
Does Biogen’s (BIIB) Rare Disease Pipeline Gain Momentum with New Dravet Study Data? - simplywall.st
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen’s SWOT analysis: mixed outlook as Alzheimer’s drug gains traction amid stock valuation concerns - Investing.com Nigeria
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen, Stoke Release Final BUTTERFLY Study Data - Nasdaq
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer |
Oct 02 '25 |
Option Exercise |
0.00 |
26 |
0 |
503 |
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
0.64%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):